Zymeworks Inc.
zanidatamab
HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA)
Countdown
4days
FDA decision · Aug 25, 2026
What's at stake
The FDA's approval decision on zanidatamab for HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA) is due Aug 25, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 2mo ago
“PDUFA target action date of August 25, 2026”